More research is needed to demonstrate that the cost to Medicare of anti-obesity drugs like the GLP-1 inhibitors will be outweighed by a reduction in other health care spending, the Congressional Budget Office says in a blog post on 5 October.
Key Takeaways
-
Statutory change allowing Medicare Part D coverage will be a long haul; CBO sounds skeptical.
-
Data demonstrating that savings to the health care system outweighs the cost of treatment will be important for expanding coverage.
-
Obesity drugs may be held to a higher evidence standard than other chronic use drugs because the potential cost burden they pose seems so high
To date, “the evidence suggests that the amount of potential savings on cardiac care and other health care would be less than the current net federal
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
